Sermorelin vs IGF-1: What the Research Compares

Sermorelin and IGF-1 are not two versions of the same intervention. Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been studied as a secretagogue acting on the pituitary, whereas insulin-like growth factor 1 (IGF-1) is the downstream growth factor that circulates after growth hormone acts on the liver. In most published work the two appear in the same sentence because IGF-1 is the measurement used to judge whether a secretagogue such as sermorelin did anything: a 2017 clinical report in hypogonadal men described growth hormone secretagogue treatment raising serum IGF-1 levels (PMID 28830317). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question.

What each one is

Sermorelin

Sermorelin corresponds to the biologically active fragment of human GHRH. Reviews of GHRH chemistry have described this family of molecules, often written as GRF analogues, as short peptides whose native forms are rapidly degraded in plasma, which is why medicinal chemists explored PEGylation and other modifications to extend their circulating lifetime (PMID 14499707). Mechanistically, agents in this class are grouped with growth hormone secretagogues: a 2020 review of body composition management in hypogonadal males placed GHRH analogues and other secretagogues together as compounds that act upstream of endogenous growth hormone release rather than supplying the hormone itself (PMID 32257855).

IGF-1

IGF-1 is an endogenous peptide hormone produced largely by the liver in response to growth hormone signalling, and it is the analyte most often drawn in studies of this axis because it is more stable across the day than pulsatile growth hormone. A 2026 review of peptides that modulate the GH-IGF1 axis treated circulating IGF-1 as the shared endpoint across very different compounds, and it contrasted the controlled clinical evidence base with the uncontrolled self-administration environment in which many of these molecules now circulate (PMID 42395176). In other words, within the literature summarised here, IGF-1 functions mainly as an outcome variable and a biomarker rather than as a peptide that investigators administered.

Side-by-side comparison

Is there a head-to-head trial?

No direct comparison exists in the literature summarised here. No randomised trial assigned one group to sermorelin and another to administered IGF-1 with shared endpoints. That absence is structural rather than accidental: because IGF-1 is what rises when a secretagogue works, a trial comparing the two would be comparing an input with its own output. The 2026 review of GH-IGF1-modulating peptides described exactly this framing, noting that the clinical evidence for these compounds is organised around the axis as a whole rather than around head-to-head contests between agents (PMID 42395176). Anyone looking for a winner will not find one in the published record, and this page does not supply one.

What the sermorelin-side literature measured

The most directly relevant clinical signal in the verified set comes from men with hypogonadism. Researchers reported that growth hormone secretagogue treatment in hypogonadal men raised serum insulin-like growth factor-1 levels, with IGF-1 serving as the primary biochemical endpoint (PMID 28830317). The accompanying 2020 review examined the same population and asked whether secretagogues had a defensible place alongside, or beyond, androgen receptor-directed therapy in managing body composition, concluding that the class warranted discussion specifically because it works through endogenous growth hormone release (PMID 32257855).

Separately, the pharmaceutical-chemistry literature addressed a practical obstacle rather than a clinical outcome. A 2003 review in Advanced Drug Delivery Reviews covered PEGylation of GRF analogues as a strategy for improving the stability and duration of these peptides, framing short plasma persistence as the central delivery problem for the GHRH class (PMID 14499707). Broader peptide reviews have made a similar point about translation: a 2026 review of therapeutic peptides in orthopaedics catalogued applications alongside the challenges that keep many peptide candidates short of definitive clinical evidence (PMID 41490200).

What the IGF-1-side literature measured

In the papers verified for this page, IGF-1 appears in two roles. The first is as a laboratory endpoint: the 2017 report tracked serum IGF-1 as the quantity that moved during growth hormone secretagogue treatment in hypogonadal men (PMID 28830317). The second is as the organising concept of an entire axis: the 2026 Frontiers in Endocrinology review mapped the landscape of performance-oriented peptides that modulate GH-IGF1 signalling and explicitly described a gap between what controlled clinical studies have established and what people do when self-administering these compounds (PMID 42395176).

What the verified literature does not contain is a body of trials administering IGF-1 itself and comparing those results with sermorelin. Readers should treat claims about one compound "beating" the other on fat loss, recovery, sleep or body composition as unsupported by the sources summarised here, because none of these papers ran that comparison (PMID 42395176).

Regulatory status

Regulatory standing is one place where the two genuinely differ, and it is a matter of public record rather than study data. Recombinant IGF-1 exists as a prescription biologic approved for narrow endocrine indications and is dispensed under physician supervision. Sermorelin is not currently marketed as an approved finished drug product in the United States; material labelled as sermorelin typically circulates either through compounding channels or as research-use-only chemical, which is not the same as an approved medicine. The 2026 GH-IGF1 review addressed the consequences of that grey zone directly, describing patient self-administration occurring outside the controlled settings where clinical evidence is generated (PMID 42395176). None of this is legal advice.

Safety and Adverse Events: What Studies Report

Neither evidence base offers a long-horizon safety comparison, so the available reports should be read as individual observations rather than as rates. A 2026 case report described anterior cervical osteophyte-related dysphagia in a long-term growth hormone user, illustrating that sustained stimulation of this axis has been associated with skeletal overgrowth findings in at least one documented patient (PMID 42465868). The 2026 review of GH-IGF1-modulating peptides raised the parallel concern that self-administration outside clinical oversight removes the monitoring that would normally detect such problems (PMID 42395176).

On the secretagogue side, the 2020 review of hypogonadal males discussed this class in the context of clinical management and surveillance rather than presenting it as free of trade-offs (PMID 32257855), and the 2026 orthopaedic peptide review listed safety characterisation and regulatory hurdles among the open challenges for therapeutic peptides generally (PMID 41490200). No dosing information appears on this page because the verified sources do not support a dose comparison between the two.

Limitations readers should hold onto

• No head-to-head data. The comparison is assembled from separate literatures, not from a trial that randomised participants between them (PMID 42395176).
• Narrow populations. The clearest clinical secretagogue signal came from hypogonadal men, not from healthy or athletic populations (PMID 28830317).
• Biomarker is not benefit. A rise in serum IGF-1 was the measured outcome in that report, and a laboratory change is not the same as a demonstrated clinical result (PMID 28830317).
• Delivery remains unsolved for the class. Formulation reviews treated the short plasma persistence of GRF analogues as the defining engineering problem (PMID 14499707).
• Case reports are signals, not frequencies. One documented dysphagia case in a long-term growth hormone user cannot establish how often such an event occurs (PMID 42465868).

How the two fit together conceptually

A useful way to hold the relationship is sequential rather than competitive: GHRH signalling sits upstream, pituitary growth hormone release sits in the middle, and hepatic IGF-1 sits downstream as the circulating readout. The 2020 review framed secretagogues precisely as upstream agents that rely on an intact pituitary response (PMID 32257855), while the 2026 axis review treated IGF-1 as the common currency by which heterogeneous compounds are compared (PMID 42395176). The study designs reflect that logic, the intervention is given upstream and the measurement is taken downstream (PMID 28830317).

Related reading

• Sermorelin: what the literature covers
• IGF-1: what the literature covers

References

• Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels (American Journal of Men's Health, 2017)
• Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males (Translational Andrology and Urology, 2020)
• PEGylation of growth hormone-releasing hormone (GRF) analogues (Advanced Drug Delivery Reviews, 2003)
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Frontiers in Endocrinology, 2026)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)
• Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report (Frontiers in Surgery, 2026)